Teclistamab (Anti-BCMA & CD3)

Synonyms: JNJ-64007957

For research use only. Not for use in humans.

Home Biosimilar Antibodies Immunology & Inflammation CD markers inhibitor Teclistamab (Anti-BCMA & CD3)

Teclistamab is a humanized bispecific IgG4 monoclonal antibody that targets CD3 on T cells and B-cell maturation antigen (BCMA) on multiple myeloma (MM) cells. It triggers a T cell-mediated immune response, leading to the elimination of BCMA-positive cells and exhibits the potential to treat patients with triple-class exposed relapsed/refractory multiple myeloma (R/RMM). MW: 143.66 KD.

Teclistamab (Anti-BCMA & CD3)

Purity & Quality Control

Batch: A402901 Purity: 99% Protein concentration: 5.327mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 0
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description Teclistamab is a humanized bispecific IgG4 monoclonal antibody that targets CD3 on T cells and B-cell maturation antigen (BCMA) on multiple myeloma (MM) cells. It triggers a T cell-mediated immune response, leading to the elimination of BCMA-positive cells and exhibits the potential to treat patients with triple-class exposed relapsed/refractory multiple myeloma (R/RMM). MW: 143.66 KD.

Product Details

CAS No. 2119595-80-9
Source CHO
Storage
(From the date of receipt)		 -80℃(avoid freeze-thaw cycles)

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.